+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Gaucher's disease type I - Pipeline Insight, 2024 - Product Thumbnail Image

Gaucher's disease type I - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 40 Pages
  • Global
From
Gaucher's Disease Type III - Pipeline Insight, 2024 - Product Thumbnail Image

Gaucher's Disease Type III - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Argininosuccinic aciduria - Pipeline Insight, 2024 - Product Thumbnail Image

Argininosuccinic aciduria - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Krabbe Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Krabbe Disease - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Bardet-Biedl Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Bardet-Biedl Syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Central Precocious Puberty - Pipeline Insight, 2024 - Product Thumbnail Image

Central Precocious Puberty - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Empagliflozin Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

Empagliflozin Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • February 2024
  • 30 Pages
  • Global
From
Fibroblast Growth Factor 2 (FGFR2) - Pipeline Insight, 2024 - Product Thumbnail Image

Fibroblast Growth Factor 2 (FGFR2) - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 100 Pages
  • Global
From
Enhancer of zeste homolog 2 protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Enhancer of zeste homolog 2 protein inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Androgen receptor antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Androgen receptor antagonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
From
BRD4 protein inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

BRD4 protein inhibitor - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Capsid protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Capsid protein inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
ACVR1 protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

ACVR1 protein inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
MALT1 protein inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

MALT1 protein inhibitor - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
MCL1 protein inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

MCL1 protein inhibitor - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
ATR protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

ATR protein inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
ANGPTL3 protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

ANGPTL3 protein inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Viral core protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Viral core protein inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more